KCM
KROS icon

Kennedy Capital Management’s Keros Therapeutics KROS Stock Holding History

Kennedy Capital Management’s Portfolio KROS Stock Details KROS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q3 		– Sell
-58,119
Closed -$2.34M – 693
2023
Q2 		$2.34M Buy
58,119
+34,239
+143% +$1.5M 0.05% 430
2023
Q1 		$1.02M Buy
23,880
+390
+2% +$19.7K 0.03% 485
2022
Q4 		$1.13M Sell
23,490
-16
-0.1% -$747 0.03% 477
2022
Q3 		$884K Sell
23,506
-23,676
-50% -$821K 0.03% 496
2022
Q2 		$1.3M Buy
47,182
+844
+2% +$37K 0.04% 447
2022
Q1 		$2.52M Sell
46,338
-367
-0.8% -$18.8K 0.06% 417
2021
Q4 		$2.73M Buy
46,705
+2,918
+7% +$146K 0.06% 419
2021
Q3 		$1.73M Sell
43,787
-679
-2% -$24.2K 0.04% 482
2021
Q2 		$1.89M Sell
44,466
-23,514
-35% -$1.27M 0.04% 482
2021
Q1 		$4.18M Buy
+67,980
New +$4.31M 0.08% 408

Other funds holding KROS

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Alkeon Capital Management
Alkeon Capital Management New York $74.1B AUM 71.18% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
B
Braidwell Stamford, Connecticut $2.7B AUM 88.53% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
CS
Candriam SCA Strassen, Luxembourg, Luxembourg $22.2B AUM 58.34% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $32.4B AUM 58.5% 1-Year Est. Return

Kennedy Capital Management's KROS Position: Q3 2023 in Review

Kennedy Capital Management sold out of Keros Therapeutics (KROS) in Q3 2023, closing a stake of 58,119 shares — an estimated $2.34M sold.

Kennedy Capital Management first reported a position in KROS in Q1 2021 and held it in 10 quarters. The position peaked at $4.18M in Q1 2021. 107 funds tracked by Wall St. Rank hold KROS as of Q3 2023.

  • Kennedy Capital Management reported no remaining Keros Therapeutics position as of Q3 2023 after selling out during the quarter.
  • Kennedy Capital Management sold 58,119 Keros Therapeutics shares in Q3 2023, an estimated $2.34M.
  • Kennedy Capital Management first reported a position in Keros Therapeutics in Q1 2021 and held it in 10 quarters.
  • Kennedy Capital Management's Keros Therapeutics position peaked at $4.18M in Q1 2021.
  • 107 funds tracked by Wall St. Rank held Keros Therapeutics as of Q3 2023.

Based on Kennedy Capital Management's 13F filing for Q3 2023, filed 14 Nov 2023.